1. Home
  2. WK vs ADPT Comparison

WK vs ADPT Comparison

Compare WK & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Workiva Inc.

WK

Workiva Inc.

HOLD

Current Price

$61.67

Market Cap

3.2B

Sector

Technology

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$23.53

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WK
ADPT
Founded
2008
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.2B
2.7B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
WK
ADPT
Price
$61.67
$23.53
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
9
Target Price
$95.30
$17.78
AVG Volume (30 Days)
677.1K
2.7M
Earning Date
05-05-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
52.53
63.89
EPS
0.58
N/A
Revenue
$884,568,000.00
$276,976,000.00
Revenue This Year
$20.85
$3.98
Revenue Next Year
$15.43
$22.72
P/E Ratio
$106.47
N/A
Revenue Growth
19.75
54.77
52 Week Low
$43.34
$11.85
52 Week High
$97.10
$24.96

Technical Indicators

Market Signals
Indicator
WK
ADPT
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
WK
ADPT

About WK Workiva Inc.

Workiva Inc is an AI-powered platform for trust, transparency, and accountability. Accounting, finance, sustainability, risk, and audit teams rely on Workiva for their mission-critical work. It transforms how customers connect data, unify processes, and empower teams in a secure, AI-powered, audit-ready, collaborative platform. Company's Geographical region consist of USA, Netherland, UK, and Others. Majority of revenue is from USA.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: